For clinical purposes, it is particularly important to consider the fact that while brain AChE activity continuously declines, BuChE activity increases continuously during disease progression [16,17]. Clinical data is therefore mounting to suggest that the use of agents with the ability to effectively inhibit BuChE as well as AChE may represent an additional therapeutic strategy for the ongoing management of AD [18,19].